This profile hasn't yet passed our validation checks
Submit your email to push it up the queue
Correvio Pharma Corp.
Correvio Pharma Corp., a prominent player in the biopharmaceutical industry, is headquartered in Canada and operates across key regions globally. Founded in 2013, the company has made significant strides in developing innovative therapies for patients with cardiovascular and infectious diseases. Correvio is renowned for its core products, including Brinavess (vernakalant), a unique antiarrhythmic agent designed for the rapid conversion of atrial fibrillation. This product, along with its commitment to advancing medical science, positions Correvio as a leader in its field. With a focus on improving patient outcomes, Correvio Pharma has achieved notable milestones, establishing a strong market presence and a reputation for excellence in drug development. The company continues to drive innovation, aiming to address unmet medical needs in the healthcare landscape.
DitchCarbon Score
How does Correvio Pharma Corp.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Correvio Pharma Corp.'s score of 25 is lower than 56% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Correvio Pharma Corp.'s reported carbon emissions
Correvio Pharma Corp., headquartered in Canada, currently does not report any specific carbon emissions data, as indicated by the absence of emissions figures. The company is a current subsidiary of ADVANZ PHARMA Corp. Limited, which may influence its climate commitments and reporting practices. As of now, Correvio Pharma Corp. has not established any documented reduction targets or climate pledges. The lack of specific emissions data and reduction initiatives suggests that the company may still be in the early stages of developing a comprehensive climate strategy. Given the context of the pharmaceutical industry, it is essential for companies like Correvio to align with broader sustainability goals and industry standards, particularly in light of increasing regulatory pressures and stakeholder expectations regarding environmental responsibility.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Correvio Pharma Corp. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
